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Alpha1-antitrypsin (a1-AT) is the most abundant circulating inhibitor of serine proteases and therefore is essential
to normal protease–anti-protease homeostasis. Inheritance of two parental a1-AT deficiency alleles is associated
with a substantially increased risk for development of emphysema and liver disease. In very rare circumstances
individuals may inherit a1-AT null alleles. Null a1-AT alleles are characterized by the total absence of serum a1-AT.
These alleles represent the extreme end in a continuum of alleles associated with a1-AT deficiency. The molecular
mechanisms responsible for absence of serum a1-AT include splicing abnormalities, deletion of a1-AT coding exons
and premature stop codons. While these alleles comprise only a small proportion of a1-AT alleles associated with
profound a1-AT deficiency, studies of their molecular mechanisms provide valuable insights into the structure, gene
expression and intracellular transport of a1-AT.
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The a1-antitrypsin (a1-AT) gene locus is designated PI and
has been mapped to 14q32.1, near the immunoglobulin
heavy chain gene cluster (1–5). It resides in a gene cluster
which includes cortisol binding globulin, a1-antichymo-
trypsin, a1-AT pseudogene and protein C inhibitor (Fig. 1)
(1–5). The a1-AT gene is composed of seven exons spanning
12 kb (Fig. 2) (1–6). The transcription and translation of a1-
AT is similar to other secreted glycoproteins. Transcrip-
tional regulation occurs in at least two dierent sites within
the gene and modulation factors include several liver
specific factors and cytokines including IL-1b and IL-6
and TNFa (2,3). Translation of a1-AT mRNA results in a
418 amino acid protein, including a 24 amino acid signal
peptide (1–6). In the rough endoplasmic reticulum mem-
brane the signal peptide is cleaved from the polypeptide and
glycosylation begins during protein folding. After transport
to the cis-golgi the carbohydrate sidechains are trimmed
and complex residues are added. Following processing in
the golgi, the 52 kDa globular glycoprotein is rapidly
secreted into the serum. While the principal site of synthesis
is the liver parenchymal cell, a1-AT synthesis also occurs in
mononuclear phagocytes, intestinal epithelium, kidney
parenchyma and several other sites (2–5).
a1-AT deficiency, a common autosomal recessive inher-
ited disease among Caucasians, is characterized by reduc-Correspondence should be addressed to: Dr Mark Brantly,
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0954-6111/00/0C000S7+05 $35?00/0tion in serum a1-AT in association with emphysema and,
occasionally, liver disease. Most individuals with a1-AT
deficiency are homozygous for the PI*Z allele (1–5).
Approximately 5% of a1-AT deficient individuals have
other deficiency alleles including those associated with low
a1-AT serum levels or null alleles which do not express a1-
AT (2,4,5,7). Null alleles, while rarely causing a1-AT
deficiency, represent an opportunity to understand the
relationship between gene sequence changes and mechan-
isms of a1-AT expression. The various a1-AT null alleles
result from several dierent molecular mechanisms, includ-
ing large gene deletions, intron mutations, nonsense
mutations, frameshift mutations, and missense mutations
associated with amino acid substitutions in potentially
critical structural elements (2,4,5,7–21) (Table 1). Interest-
ingly, and in contrast to the b thalassaemias, no mutations
in the promotor regions of the a1-AT gene have been
reported in association with the complete absence or partial
deficiency of a1-AT.
Null alleles as a result of large gene
deletions
The existence of a1-AT null alleles was first noted in the
early 1970s by several investigators. Complete deletions of
the a1-AT gene are rare and comprise only a small fraction
of the total number of null alleles. The first documented
complete deletion of the coding regions of a1-AT was
QOisola di procida (8).# 2000 HARCOURT PUBLISHERS LTD
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RNA splice sites
Two null alleles have been identified which likely directly
involve the formation of stable mRNA transcripts follow-
ing RNA splicing. QOwest is characterized by a single G to
T base substitution at position 1 of intron II, a highlyFIG. 1. SERPIN gene cluster. Located on chromosome 14
at 32.1 of the long arm, are the homologous gene loci for
a1-antichymotrypsin (AACT), protein C inhibitor (PCI),
a1-antitrypsin (PI), a1-antitrypsin-like gene (PIL) and
cortisol binding globulin (CBG).
FIG. 3. Location of sequence defined a1-antitrypsin alleles.
a1-AT null alleles are named after the birth city of the
oldest member transmitting the null allele in the pedigree.
Top to bottom, left, amino terminal end (NH2), null
alleles designated by ‘QO’ with arrows identifying the
approximated location of the mutation, to carboxyl
terminal end (COOH). Y, T, I, W, K, H, G, E, L, are the
one letter codes for the amino acids Tyr, Thr, Ile, Trp,
Lys, His, Gly, Glu and Leu, respectively; Z indicates a
stop codon. Right, from top to bottom, 5’ end of mRNA/
cDNA, beginning with the start codon (ATG), coding
sequence for the 24 amino terminal signal peptide, sites of
N-linked carbohydrate attachments (CHO), active site
(M358) and stop codon (TAA). QOmattawa, bolton,
clayton, and saarbruecken all originate in a region of the
gene associated with slippage misalignment.
/———————————————————————
FIG. 2. Genomic organization of the a1-antitrypsin
gene. The a1-AT gene is composed of seven exons: Ia, Ib,
Ic, II-V, and spans about 12 kb. In macrophages,
transcription begins in exon Ia. In hepatocytes,
transcription begins in exon Ic. Translation begins at the
ATG codon in exon II. The protein begins with a signal
peptide which directs the peptide through the membrane
of the rough endoplasmic reticulum. Asn46-CHO, Asn83 -
CHO, Asn247-CHO are the sites of carbohydrate
attachment. The a1-AT active site (methionine residue
358)
is encoded in exon V. Translation of the protein ceases at
the TAA stop codon in exon V that is followed by the
signal for polyadenylation.
Table 1. Null a1-antitrypsin alleles determined by DNA sequencing
{
Allele Base} Exon} Mutation
QO granite falls M1(Ala213) II Tyr 160 TAC?delete C? 5’ shift? stop 160 TAG
QO bellingham M1 (Val213) III Lys 217 AAG? stop 217 TAG
QO mattawa M1 (Val213) V Leu 353 TTA? insert T? 3’ shift? stop 376 TGA
QO bolton M1 (Val213) V Pro 362 CCC? delete C? 5’ shift? stop 373 TAA
QO hong kong M2 IV Leu 318 CTC? delete TC? 5’ shift? stop 334 TAA
QO ludwigshafen M2 II Ile 92 ATC?Asn AAC
QO isola di procida – II–V 10 kb deletion of exons II–V, DII-V
QO clayton M1 (Val213) V Pro 362 CCC? insert C? 3’ shift? stop376 TGA
QO bonny blue M1 (Val213) * DG deletion position #1 of intron II splice acceptor
QO new hope M1 (Ala213) IV,V Gly 320 GGG?Glu GAG/Glu 342 GAG?Lys AAG
QO trastevere M1 (Val213) III Trp194 TGG?Stop TGA
QO kowloon M1 (Val213) II Tyr 38 TAC?Stop TAA
QO saarbruecken M1(Ala213) V Pro 362 CCC? insert C? 3’ shift? stop376 TGA
QO lisbon M1 (Val213) II Thr 68 ACC? Ile ATC
QO west M1 (Val213) * G?T position #1 of intron II splice donor substitution
{References 7–18, 21.
}Indicates the base allele.
}Indicates in which exon the mutation is located.
*Mutation in a non-coding portion of the a1-AT gene.
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sites. Metabolic labeling of NIH-3T3 cells transfected with
a plasmid vector containing an a1-AT minigene with the
QOwest mutation demonstrated an absence of detectable
immunoprecipitable a1-AT, confirming that the G to T
mutation is responsible for the observed null phenotype.
QOwest a1-AT minigene transfected cells expressed 25–100
fold less a1-AT mRNA than a normal control. DNA
sequencing of polymerase chain reaction amplified mRNA
obtained from transfected cells demonstrated a cryptic
splice site 84 bases upstream from the normal splice site.
Translation of this sequence would result in an in-frame
deletion of amino acids Gly164 to Lys191, corresponding
structurally to a-helix F and b-sheet 3A of the a1-AT
protein (18,19). QObonny blue is a deletion of a guanine at
position 1 of the exon II splice acceptor site (7). The
molecular consequences of this mutation have not been
reported.
Null alleles associated with formation
of premature termination codons
Among the a1-AT null mutations caused by formation of
premature stop codons, molecular mechanisms have
been defined for variants with no detectable mRNA
(QOgranite falls and bellingham) and alleles which produce
normal mRNA levels (QOhong kong, mattawa, bolton,
and clayton/saarbruecken) (Table 2) (9–11,13–17,
21,22). While QOgranite falls, QObellingham and QOtras-
tevere terminate in exon II and III, the rest of the mutationscause the formation of termination codons in exon V, near
the N-terminus of the protein. The observation that
mutation-caused premature termination codons near the
end of a coding sequence are associated with normal
mRNA content and mutations in the early coding
sequence are associated with decreased steady-state cyto-
plasmic mRNA is consistent with the translational–
translocation model (22–24). In this model, translation of
the mRNA on the ribosome starts as soon as the mRNA
emerges from the nuclear pore. Mutations that cause
premature termination codons would halt the pulling
process, leaving the RNA molecule vulnerable to RNase
digestion. However mutations occurring after the penulti-
mate exon would not be recognized until the translocation
of the mRNA from the nucleus was almost complete and,
therefore, would not be associated with decreased mRNA
content (22–25).
Nonsense mutations in several genes have been reported
to decrease steady state mRNA levels (22,23). Several
possible explanations exist, including lowering the tran-
scription rate, reducing the rate of RNA processing and/or
causing unstable mature mRNA (22,23). Evaluation of
nonsense mutants in other genes however, has not
demonstrated significant lowering of the transcription rate.
There are several examples which illustrate the critical role
of mRNA stability in determining levels of gene expression.
Elements of the RNA structure including the cap structure,
5’UTR secondary structures, premature termination co-
dons, open reading frame sequences, 3’UTR sequences and
the poly (A) tail all may contribute to mRNA stability
(22,23). Alteration in the secondary structure of mRNA
does not appear to aect stability. Since most missense
Table 2. Molecular mechanisms of a1-antitrypsin associated with premature termination codons
{
Allele Mutation Exon} mRNA(%)} Protein{ Phenotype
QO kowloon c186 C?A, Val38 Stop II ND
k
ND Null
QO granite falls c552 del C, Yal160Stop II 0 None Null
QO trastevere c654 G?A, Trp194Stop III 63 31 kDa Null
QO bellingham c721 A?G, Lys217Stop III 0 None Null
QO hong kong c1026 del TC,Val334Stop V 75–100 45 kDa Null
QO mattawa c1131 ins T, Glu376Stop V 75–100 50 kDa Null
QO bolton c1158 del C, Leu373Stop V 75–100 50 kDa Null
QO clayton c1158 ins C, Glu376Stop V 75–100 50 kDa Null
QO saarbruecken* c1158 ins C, Glu376Stop V 75–100 50 kDa Null
{References 7, 9–11, 13–17.
}Exon containing the termination codon.
}Percent of normal total mRNA content.
{Apparent molecular mass of truncated protein.
k
Not determined.
*The molecular mechanisms for QOsaarbruecken and QOclayton are the same since they only dier by their background
allele.
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revertants of low mRNA nonsense mutants show normal
mRNA levels, it is possible that the functional consequence
of a nonsense codon itself is a decreased mRNA level
(22,23).
The position of premature termination codons in the a1-
AT coding sequence clearly has an important eect on the
a1-AT mRNA level (Table 2). QOgranite falls, which has a
premature termination at exon II, does not express mRNA,
whereas QOhong kong, QOmattawa, QObolton and
QOclayton have termination codons in exon V and near
normal mRNA levels (Table 2). When a premature
termination codon is positioned between these extremes,
as in the case of QOtrastevere, mRNA expression is
reduced. In general, a1-AT mRNA cellular content depends
on the distance of the nonsense codon from the initiator
codon (22–24). QObellingham appears to be an exception
to this observation since this allele is associated with total
absence of detectable mRNA and despite the presence of its
termination codon is 3’ to the QOtrastevere stop codon.
This observation demonstrates that some elements within
the coding region may be more important than others in
conferring mRNA stability. Thus, a1-AT mRNA stability is
not simply a function of the distance of a nonsense
mutation from the initiator codon (22,23). The eect of
a1-AT nonsense mutations, specifically the QOtrastevere
mutation, on mRNA levels is consistent with the transloca-
tion/translation explanation of nonsense mutations on
mRNA stability (22).
Similar to other truncated a1-AT variants, the QOtras-
tevere mutant protein is retained in the rough endo-
plasmic reticulum (RER)/pre-Golgi compartment and
rapidly degraded. Although there is a substantial dierence
in the degree of truncation of QOtrastevere (193 amino
acids) and QOhong kong (333 amino acids), QOtrastevere
has a half-life similar to that of QOhong kong (t1/2=2h)rather than that of QOclayton (t1/2=6?5 h) which has 375
amino acids (Table 2) (17). This observation indicates that
disposal of truncated a1-AT may involve determinants not
specifically related to the degree of truncation. Similar to Z
a1-AT, QOtrastevere a1-AT degradation was inhibited by
the translation inhibitor cycloheximide, but is not inhibited
by agents that disrupt lysosomal function (17,26–28).
However, while Z a1-AT degradation was inhibited by the
metabolic poisons, NaN3/NaF or 2,4-dinitrophenol/2-
deoxy-D-glucose, QOtrastevere degradation was only
inhibited by NaN3/NaF, indicating that dierent pathways
of intracellular degradation may exist for some truncated
and misfolded proteins (17,26–28).
With the exception of promoter mutations, a1-AT null
mutations reflect most mechanisms currently known to be
associated with the complete absence of a single gene
product. Observations made as a result of these experiments
in nature may prove valuable in understanding the
molecular basis of liver disease and expand our general
knowledge of quality control mechanism-associated dis-
posal of misfolded proteins.
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